Literature DB >> 2561181

Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.

M A Boogaerts, G E Verhoef, P Zachee, H Demuynck, L Verbist, K De Beule.   

Abstract

Seventy-two patients with haematological malignancies were treated prophylactically with itraconazole during remission induction therapy. The incidence of proven fungal infections was 18%, of which 12.5% were fatal. Aspergillus, Torulopsis and Candida proved to be major invasive pathogens. Plasma levels of itraconazole were monitored for all patients. The occurrence of fungal infection is significantly greater in the group where no therapeutic plasma levels were obtained during at least two weeks. There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients. The influence of itraconazole on liver function tests could not be separated from concomitant cytostatic or antibiotic treatment. No jaundice directly related to itraconazole could be found. During itraconazole prophylaxis a shift from classic pathogens such as Aspergillus and Candida, to Fusarium, Torulopsis and Mucor, may be seen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561181     DOI: 10.1111/j.1439-0507.1989.tb02299.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  38 in total

1.  Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis.

Authors:  C Schmitt; Y Perel; J L Harousseau; S Lemerle; E Chwetzoff; J P le Moing; J C Levron
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Role of itraconazole in haematology/oncology.

Authors:  N A Pandya; A A Atra; U Riley; C R Pinkerton
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

3.  Sputum itraconazole concentrations in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; A Lesne-Hulin; G Lenoir; E Singlas; P Berche; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

5.  Possible failure of itraconazole in preventing fungal infection in a neutropenic leukaemia patient.

Authors:  W D Hendriks; W Sizoo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

Review 6.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

7.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

8.  Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.

Authors:  P Montesinos; R Rodríguez-Veiga; B Boluda; D Martínez-Cuadrón; I Cano; A Lancharro; J Sanz; M J Arilla; F López-Chuliá; I Navarro; I Lorenzo; M Salavert; J Pemán; P Calvillo; J Martínez; N Carpio; I Jarque; G F Sanz; M A Sanz
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

9.  Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole.

Authors:  Takehiko Mori; Yoshinobu Aisa; Jun Kato; Yukinori Nakamura; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.490

Review 10.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.